Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding Domain

被引：0
作者：
Romanenko, Ya. O. [1 ]
Silkina, M. V. [1 ]
Kartseva, A. S. [1 ]
Marin, M. A. [1 ]
Shkuratova, M. A. [1 ]
Makarova, M. A. [1 ]
Ryabko, A. K. [1 ]
Konyshkova, D. A. [1 ]
Zeninskaya, N. A. [1 ]
Khlyntseva, A. E. [1 ]
Shemyakin, I. G. [1 ]
Firstova, V. V. [1 ]
机构：
[1] Fed Budget Inst Sci State Res Ctr Appl Microbiol &, Obolensk 142279, Moscow, Russia
来源：
ACTA NATURAE | 2023年 / 15卷 / 01期
关键词：
COVID-19; SARS-CoV-2; receptor-binding domain; human monoclonal antibody; virus-neutral-izing activity;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the up-per respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae fam-ily, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.
引用
收藏
页码：81 / 86
页数：6
相关论文
共 50 条
  • [1] Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
    Mehalko, Jennifer
    Drew, Matthew
    Snead, Kelly
    Denson, John-Paul
    Wall, Vanessa
    Taylor, Troy
    Sadtler, Kaitlyn
    Messing, Simon
    Gillette, William
    Esposito, Dominic
    PROTEIN EXPRESSION AND PURIFICATION, 2021, 179
  • [2] Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain
    Lai, Guan-Chun
    Chao, Tai-Ling
    Lin, Shiau-Yu
    Kao, Han-Chieh
    Tsai, Ya-Min
    Lu, De-Chao
    Chiang, Yi-Wei
    Chang, Sui-Yuan
    Chang, Shih-Chung
    ANTIVIRAL RESEARCH, 2022, 200
  • [3] Conformational Dynamics of the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
    Mamchur, Aleksandra A.
    Stanishneva-Konovalova, Tatiana B.
    Mokrushina, Yuliana A.
    Abrikosova, Viktoria A.
    Guo, Yu
    Zhang, Hongkai
    Terekhov, Stanislav S.
    Smirnov, Ivan V.
    Yaroshevich, Igor A.
    BIOMEDICINES, 2022, 10 (12)
  • [4] Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain
    Huang, Ping-Han
    Tsai, Hsiao-Han
    Liao, Bo-Hung
    Lin, Yi-Ling
    Jan, Jia-Tsrong
    Tao, Mi-Hua
    Chou, Yu-Chi
    Hu, Che-Ming Jack
    Chen, Hui-Wen
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 654 - 655
  • [5] Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast
    Nagar, Gaurav
    Jain, Siddharth
    Rajurkar, Meghraj
    Lothe, Rakesh
    Rao, Harish
    Majumdar, Sourav
    Gautam, Manish
    Rodriguez-Aponte, Sergio A.
    Crowell, Laura E.
    Love, J. Christopher
    Dandekar, Prajakta
    Puranik, Amita
    Gairola, Sunil
    Shaligram, Umesh
    Jain, Ratnesh
    VACCINES, 2023, 11 (10)
  • [6] Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
    Deliyannis, Georgia
    Gherardin, Nicholas A.
    Wong, Chinn Yi
    Grimley, Samantha L.
    Cooney, James P.
    Redmond, Samuel J.
    Ellenberg, Paula
    Davidson, Kathryn C.
    Mordant, Francesca L.
    Smith, Tim
    Gillard, Marianne
    Lopez, Ester
    McAuley, Julie
    Tan, Chee Wah
    Wang, Jing J.
    Zeng, Weiguang
    Littlejohn, Mason
    Zhou, Runhong
    Chan, Jasper Fuk-Woo
    Chen, Zhi-wei
    Hartwig, Airn E.
    Bowen, Richard
    Mackenzie, Jason M.
    Vincan, Elizabeth
    Torresi, Joseph
    Kedzierska, Katherine
    Pouton, Colin W.
    Gordon, Tom P.
    Wang, Lin-fa
    Kent, Stephen J.
    Wheatley, Adam K.
    Lewin, Sharon R.
    Subbarao, Kanta
    Chung, Amy W.
    Pellegrini, Marc
    Munro, Trent
    Nolan, Terry
    Rockman, Steven
    Jackson, David C.
    Purcell, Damian F. J.
    Godfrey, Dale I.
    EBIOMEDICINE, 2023, 92
  • [7] Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis
    Baig, Abdul Mannan
    Khaleeq, Areeba
    Syeda, Hira
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2792 - 2803
  • [8] Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain
    Anzai, Itsuki
    Fujita, Junso
    Ono, Chikako
    Kosaka, Yoichiro
    Miyamoto, Yuki
    Shichinohe, Shintaro
    Takada, Kosuke
    Torii, Shiho
    Taguwa, Shuhei
    Suzuki, Koichiro
    Makino, Fumiaki
    Kajita, Tadahiro
    Inoue, Tsuyoshi
    Namba, Keiichi
    Watanabe, Tokiko
    Matsuura, Yoshiharu
    MICROBIOLOGY SPECTRUM, 2024, 12 (04)
  • [9] Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)/ACE2 interaction In vitro
    Omotuyi, Olaposi
    Olatunji, Olusina M.
    Nash, Oyekanmi
    Oyinloye, Babatunji
    Soremekun, Opeyemi
    Ijagbuji, Ayodeji
    Fatumo, Segun
    MICROBIAL PATHOGENESIS, 2023, 176
  • [10] Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung
    Shin, Hye Jin
    Ku, Keun Bon
    Kim, Hae Soo
    Moon, Hyun Woo
    Jeong, Gi Uk
    Hwang, Insu
    Yoon, Gun Young
    Lee, Sunhee
    Lee, Sumin
    Ahn, Dae-Gyun
    Kim, Kyun-Do
    Kwon, Young-Chan
    Kim, Bum-Tae
    Kim, Seong-Jun
    Kim, Chonsaeng
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (14): : 3786 - 3794
12345